Peptide library / Digestive & weight / Glepaglutide
Glepaglutide
An investigational long-acting GLP-2 analog for short bowel syndrome, dosed once or twice weekly.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Reduce parenteral nutrition dependence in short bowel syndromeLarge trials
How it is thought to work
Glepaglutide acts on the same GLP-2 pathway as teduglutide but with a longer duration of action.
What the evidence shows
A phase 3 trial reported improvement in parenteral support needs. The FDA asked for an additional trial before approval.
Safety and unknowns
Abdominal discomfort and injection site reactions were reported.
Regulatory status
Not approved in the United States. Regulators requested further study.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Digestive & weight
KPV
Wellness and performanceA three amino acid fragment of alpha-MSH studied for gut and skin inflammation, mostly in animals.
Larazotide
In clinical trialsAn eight amino acid peptide once tested as an add-on to a gluten-free diet in coeliac disease.
Gallium Ga-68 dotatate
FDA-approvedA radioactive peptide used in PET scans to find neuroendocrine tumors.
General information, not medical advice. Do not buy or inject unregulated peptides.